MiniMed Group Inc (NASDAQ:MMED) Receives $21.33 Average Target Price from Analysts

Shares of MiniMed Group Inc (NASDAQ:MMED) have been given a consensus rating of “Moderate Buy” by the fifteen research firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and twelve have given a buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $21.3333.

MMED has been the subject of several analyst reports. Mizuho initiated coverage on MiniMed Group in a research note on Tuesday, March 31st. They set an “outperform” rating and a $21.00 price target for the company. Deutsche Bank Aktiengesellschaft initiated coverage on MiniMed Group in a research note on Tuesday, March 31st. They set a “buy” rating and a $20.00 price target for the company. BTIG Research initiated coverage on MiniMed Group in a research note on Tuesday, March 31st. They set a “buy” rating and a $25.00 price target for the company. Morgan Stanley initiated coverage on MiniMed Group in a research note on Tuesday, March 31st. They set an “overweight” rating and a $19.00 price target for the company. Finally, William Blair initiated coverage on MiniMed Group in a research note on Tuesday, March 31st. They set an “outperform” rating for the company.

MiniMed Group Price Performance

Shares of MMED opened at $14.77 on Friday. The company has a 50 day simple moving average of $13.02. MiniMed Group has a 52-week low of $10.65 and a 52-week high of $20.48.

MiniMed Group (NASDAQ:MMED) last posted its quarterly earnings data on Wednesday, June 3rd. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.46). The firm had revenue of $837.00 million during the quarter. The firm’s revenue for the quarter was up 15.6% compared to the same quarter last year.

MiniMed Group Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.